Kunming Pharmaceuticals, Inc.
10
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
Role: lead
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects
Role: lead
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
Role: lead
A Trial to Evaluate KPC000154 Tablets in Healthy Subjects
Role: lead
Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
Role: lead
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
Role: collaborator
Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors
Role: lead
Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.
Role: lead
Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection
Role: lead
Exploratory Study of DHA in Systemic Lupus Erythematosus Patients
Role: lead
All 10 trials loaded